SCHEMBL19414400

SCHEMBL19414400

COc1cc(OC)cc(-c2n[nH]c3ncnc(N)c23)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 1/20 0.47
CYP1B1 Q16678 1/20 0.47
PIK3CD O00329 4/20 0.44
KDR P35968 4/20 0.44
ABL1 P00519 3/20 0.44
EGFR P00533 3/20 0.44
HCK P08631 3/20 0.44
SRC P12931 3/20 0.44
PIK3CA P42336 3/20 0.44
PIK3CB P42338 3/20 0.44
MTOR P42345 3/20 0.44
PIK3CG P48736 3/20 0.44
EPHB4 P54760 3/20 0.44
PRKDC P78527 3/20 0.44
PI4KB Q9UBF8 3/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HSD17B10 Q99714 1/20 0.44
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11670 0.91 EGFR (0.41) CYP1A1CYP1B1PIK3CDKDRABL1
SCHEMBL152637 0.91 PIK3CD (0.49) CYP1A1CYP1B1PIK3CDKDRABL1
SCHEMBL145785 0.86 SRC (0.56) PIK3CDKDRABL1EGFRHCK
SCHEMBL16783676 0.86 BACE1 (0.40) CYP1A1CYP1B1PIK3CDKDRABL1
SCHEMBL149528 0.85 KDR (0.52) PIK3CDKDRABL1EGFRHCK
SCHEMBL19414291 0.83 SRC (0.40) PIK3CDKDRABL1EGFRHCK
SCHEMBL19414290 0.82 SRC (0.57) PIK3CDKDRABL1EGFRHCK
SCHEMBL18235468 0.82 KDR (0.49) PIK3CDKDRABL1EGFRHCK
SCHEMBL11975 0.82 PIK3CB (0.39) PIK3CDKDRABL1EGFRHCK
SCHEMBL22275990 0.79 PIK3CD (0.39) PIK3CDKDRABL1EGFRHCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
US-9775841-B2 Compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2017-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A CYP1A1 2408/4885CYP1B1 1900/4885PIK3CD 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.